IndraLab
Statements
BAP1 inhibits Mesothelioma. 22 / 22
|
22
reach
"Loss of BAP1 and MTAP can support the diagnosis of mesothelioma versus benign mesothelial proliferation: however, morphology (with an invasive pattern) is still the essential tool to distinguish malignant from benign disease.Molecular analyses: FISH for alterations in CDKN2A and NF2 (as IHC for BAP1 and MTAP) can be used to support the diagnosis of mesothelioma versus benign mesothelial proliferation."
reach
"A pilot study of chemotherapy treatment using previously published doses (Badhai et al., 2020), revealed CNP mice to be extremely sensitive to chemotherapy-induced toxicity, requiring reduction of both drugs to half the concentrations used in mesothelioma mouse model driven by triple deletion of Bap1, Cdkn2a and Nf2 (Badhai et al., 2020)."
reach
"Badhai et al. suggests additional mutations (Nf2 and Cdkn2ab, which are also frequently observed in human mesotheliomas), in combination with BAP1, led to the rapid onset of mesothelioma in 100% of mice and BAP1 deletion alone caused mesotheliomas in 1 out of 20 mutant mice (5%) in the absence of asbestos exposure (Badhai et al., 2020)."